Why cancer advocates are leaving X

Plus: Kura licenses leukemia drug to Japanese drugmaker

November 22, 2024 Check out STAT+

Sponsored By

MAURO PIMENTEL/AFP via Getty Images Opinion: Why cancer advocates like me are leaving X It's sad to see the era of Twitter cancer communities end. But X isn't worth the effort anymore for me. By Janet Freeman-Daily STAT+ | Kura licenses leukemia drug to Japanese drugmaker The Kura-Kyowa tie-up comes days after a competitor, Syndax Pharmaceuticals, won U.S. approval for a similar drug.  By Adam Feuerstein Pfizer's new R&D head, a VC deep-dive, and a new FDA commissioner? On STAT's podcast, hear about what's in store for biotech VCs in 2025, Pfizer's new head of R&D, drug innovation in a second Trump term, and more. By Adam Feuerstein and Allison DeAngelis

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser